Israel - English - Ministry of Health

bayer israel ltd - riociguat - film coated tablets - riociguat 2.5 mg - riociguat - chronic thromboembolic pulmonary hypertension (cteph) adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii with • inoperable cteph, • persistent or recurrent cteph after surgical treatment, to improve exercise capacity. pulmonary arterial hypertension (pah)adempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity.efficacy has been shown in a pah population including aetiologies of idiopathic or heritable pah or pah associated with connective tissue disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - dexamethasone, quantity: 0.5 mg/ml; framycetin sulfate, quantity: 5 mg/ml; gramicidin, quantity: 0.05 mg/ml - ear drops - excipient ingredients: phenethyl alcohol; polysorbate 80; citric acid monohydrate; sodium citrate dihydrate; lithium chloride; purified water; industrial methylated spirit; hydrochloric acid; sodium hydroxide - indications as at 5 october 2000: inflammatory and allergic conditions of the ear, e.g. otitis externa. eczema of the auditory meatus is often present and causes inflammation, exudation and pruritus, which are all rapidly relieved by dexamethasone. infection,often secondary to scratching, is generally due to staphylococci, e. coli, pseudomonas and proteus spp. which respond rapidly to framycetin.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

bayer cropscience pty ltd - bacillus amyloliquefaciens strain qst 713 - wettable powder - bacillus amyloliquefaciens strain qst 713 biological-organism active 10.0 cfu/g - fungicide

United States - English - NLM (National Library of Medicine)

takeda pharmaceuticals america, inc. - lanadelumab (unii: 2372v1tkxk) (lanadelumab - unii:2372v1tkxk) - takhzyro® is indicated for prophylaxis to prevent attacks of hereditary angioedema (hae) in adult and pediatric patients aged 2 years and older. none. risk summary there are no available data on takhzyro use in pregnant women to inform any drug associated risks. monoclonal antibodies such as lanadelumab-flyo are transported across the placenta during the third trimester of pregnancy; therefore, potential effects on a fetus are likely to be greater during the third trimester of pregnancy. an enhanced pre-and postnatal development (eppnd) study conducted in pregnant monkeys at doses resulting in exposures of up to 33 times the exposure achieved (on an auc basis) at the maximum recommended human dose (mrhd) revealed no evidence of harm to the developing fetus. the background risk of major birth defects and miscarriage for the indicated population is unknown. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15

New Zealand - English - myHealthbox

bayer ag - suspension concentrate - biologics

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - lanadelumab, quantity: 300 mg - injection, solution - excipient ingredients: citric acid monohydrate; water for injections; dibasic sodium phosphate dihydrate; polysorbate 80; histidine; sodium chloride - takhzyro is indicated for routine prevention of recurrent attacks of hereditary angioedema (c1-esterase-inhibitor deficiency or dysfunction) in patients aged 12 years and older.

United States - English - NLM (National Library of Medicine)

rxhomeo private limited d.b.a. rxhomeo, inc - araneus diadematus (unii: 6t6co7r3z5) (araneus diadematus - unii:6t6co7r3z5) - araneus diadematus 2 [hp_x] - cold with chills condition listed above or as directed by the physician

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - adenosine -

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - adenosine -

Australia - English - Department of Health (Therapeutic Goods Administration)

gramicidin; framycetin sulfate; dexamethasone -